Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer.

Abstract

BACKGROUND Some studies have shown that high body mass index (BMI) is associated with inferior outcome after adjuvant therapy with anastrozole in breast cancer patients. We aimed to investigate predictive effect of BMI on clinical response to neoadjuvant therapy with exemestane in postmenopausal patients with primary breast cancer. PATIENTS AND METHODS… (More)
DOI: 10.1016/j.breast.2011.07.015

Topics

  • Presentations referencing similar topics